A Phase 2 interventional study of Cimetidine and Placebo in Erythropoietic Protoporphyria and X-linked Protoporphyria, sponsored by Amy K. Dickey, M.D.. Completed at 3 sites in United States. Open to participants aged 15 Years and older. Per ClinicalTrials.gov, last updated 2026-09-04.
Sponsored by Amy K. Dickey, M.D. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Protoporphyria, Erythropoietic with a site in United States — 4 open to participants now, 4 under way, 2 of them phase 3. Protoporphyria, Erythropoietic · United States.
Among the 18 studies in Protoporphyria, Erythropoietic with a site in United States, this one is the 10th largest by enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2022, is one of 5 in phase 2, and was the 10th registered.
29 studies on the registry are indexed under Protoporphyria, Erythropoietic; 5 are open to participants now.
Browse Protoporphyria, Erythropoietic studies →4 of the 18 studies in Protoporphyria, Erythropoietic with a site in United States are open now. Recruiting first, the newest first:
Portal Therapeutics, Inc. · Sites in United States
Ages 12+
Portal Therapeutics, Inc. · Sites in United States, Belgium, Canada and 6 more countries
Ages 12+
The American Porphyrias Expert Collaborative · Sites in United States
Ages 1 min+
Disc Medicine, Inc · Sites in United States, Australia, Belgium and 8 more countries
Ages 12+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 3 Protoporphyria, Erythropoietic studies recruiting now, 3 set no upper age limit and none stop at 75 or younger; 3 take children under 18; none take healthy volunteers.
This study: 15 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 8 · Phase 3 6
First in 2010; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 26 is below the median of 62 across 20 interventional studies indexed under Protoporphyria, Erythropoietic.
Median enrollment 77 across the 13 interventional studies, 150 across the 4 observational. Of the 13 that completed or were terminated, 9 (69%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 18 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Amy K. Dickey, M.D. as lead sponsor.
Amy K. Dickey, M.D. has 1 study filed under Protoporphyria, Erythropoietic — fewer than ten, so there is no comparison to draw.
1 of the studies in Protoporphyria, Erythropoietic with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07567131Portal Therapeutics, Inc.Observational Study of Adults and Adolescents With Erythropoietic Protoporphyria (EPP) and X-linked Porphyria (XLP) | 2027-03-01 |
Add it to your calendar (.ics) → With an account.
Among the 18 studies in Protoporphyria, Erythropoietic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP) result from genetic defects of heme biosynthesis that cause life-long, painful cutaneous sensitivity to light. The objective of this study is to determine the efficacy and safety of oral cimetidine administration for treatment of the protoporphyrias. Efficacy will be based on protoporphyrin levels, photosensitivity, and quality of life questionnaires.
Funding Source- FDA OOPD
Erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP) are genetic defects of heme biosynthesis that cause life-long, painful cutaneous sensitivity to light. EPP and XLP, collectively called the protoporphyrias, result in the accumulation of the light-sensitive molecule protoporphyrin IX initially in the bone marrow during hemoglobin synthesis and secondarily in erythrocytes, plasma, and the liver. In addition to photosensitivity, protoporphyria can also result in anemia, gallstones, and liver failure. No therapy has been demonstrated to reduce protoporphyrin levels or prevent the potentially life-threatening complications of EPP. Cimetidine has gained attention as a possible treatment for human porphyrias because of a potential off-target effect of inhibition of delta-aminolevulinate synthase (ALAS), the first enzyme of heme biosynthesis. This inhibition was first described in vitro; however, case reports of benefit in EPP have been anecdotal and uncontrolled. Therefore, the objective of this study is to determine the efficacy and safety of oral cimetidine administration in the protoporphyrias. Efficacy will be based on protoporphyrin levels, photosensitivity, and quality of life questionnaires. If the results are positive, this would be the first study providing quality evidence for an agent acting as a disease-modifying therapy for EPP. The study is also attractive because it repurposes an already approved drug with few side effects to treat a rare human disease.
The study design is a prospective, blinded, randomized, 2x2 cross-over design comparing cimetidine to placebo in patients with protoporphyria. Eligible protoporphyria patients will be randomized with equal allocation to one of two treatment sequences that will be administered over two 3-month study periods. Randomization will be stratified by site and permuted block randomization will be used to prevent chronological bias. Patients randomized to sequence 1 will receive placebo during period 1 and cimetidine during period 2. Patients randomized to sequence 2 will receive cimetidine during period 1 and placebo during period 2. Between periods, to eliminate any carry-over effects from the treatment administered in period 1, a wash-out period of 3 months will occur in which all patients receive neither cimetidine nor placebo. Three months was selected for each study period and for the wash-out period because of the rapid decline in protoporphyrin in red cells over the lifespan of the red cell (120 days), as well as to account for the time frame needed to measure light sensitivity in EPP.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cimetidine 800mg orally twice daily
Drug: Cimetidine
Placebo capsule orally twice daily
Drug: Placebo
Oral Cimetidine 800mg twice daily.
Also known as: Tagament
Placebo twice daily
Percent Change in Erythrocyte Total Protoporphyrin Level
Percent change in erythrocyte total protoporphyrin levels after treatment period versus before.
Time frame: Before and after each 3-month treatment period
Time to Prodrome
Mean daily self-reported outdoor time, in minutes, before EPP/XLP prodrome onset during the last two months of each treatment period, including days without symptoms.
Time frame: Last 2 months of each treatment period
Change in PROMIS-57 v2 Domain T-scores From Pre-treatment to End of Each 3-month Treatment Period
PROMIS-57 v2 assesses 7 health domains: Physical Function, Anxiety, Depression, Fatigue, Sleep Disturbance, Ability to Participate in Social Roles and Activities, and Pain Interference. Domain scores are converted to standardized T-scores with a U.S. general population mean of 50 and standard deviation of 10. Higher scores indicate worse outcomes for Anxiety, Depression, Fatigue, Sleep Disturbance, and Pain Interference, and better outcomes for Physical Function and Ability to Participate in Social Roles and Activities. PROMIS-57 v2 was administered immediately before and at the end of each 3-month treatment period. End-of-period PROMIS-57 v2 domain T-scores were analyzed using mixed-effects linear models adjusted for the immediately pre-treatment PROMIS-57 v2 domain T-score for that treatment period, with treatment as a fixed effect and participant as a random effect. Reported values represent least squared means for change in T-score for the cimetidine and placebo treatment periods.
Time frame: Immediately before and at the end of the 3-month cimetidine treatment period, and immediately before and at the end of the 3-month placebo treatment period
Change in PROMIS-57 v2 Pain Intensity Scores From Pre-treatment to End of Each 3-month Treatment Period
PROMIS-57 v2 Pain Intensity is a single item scored from 0 to 10, with higher scores indicating worse pain intensity. The instrument-defined possible score range is 0 to 10. This question was administered immediately before and at the end of each 3-month treatment period in this crossover trial. End-of-period PROMIS-57 v2 Pain Intensity scores were analyzed using mixed-effects linear models adjusted for the immediately pre-treatment Pain Intensity score for that treatment period, with treatment as a fixed effect and participant as a random effect. Reported values represent least squared means for change in Pain Intensity scores for the cimetidine and placebo treatment periods.
Time frame: Immediately before and at the end of the 3-month cimetidine treatment period, and immediately before and at the end of the 3-month placebo treatment period
Number of Phototoxic Reactions Per Participant During the Last 2 Months of Each Treatment Period
For each participant, the number of phototoxic reactions during the last 2 months of each 3-month treatment period was recorded. In this crossover trial, the reported outcome compares the number of phototoxic reactions per patient during cimetidine with the number during placebo.
Time frame: Last 2 months of the 3-month cimetidine treatment period and last 2 months of the 3-month placebo treatment period
Blue Light Dose
Average daily outdoor blue light dose before EPP/XLP prodrome onset during the last two months of each treatment period, including days without symptoms. Dose data for the day were excluded if the patient did not wear the dosimeter for the entire day.
Time frame: Last 2 months of each treatment period
A total of 26 patients signed the consent form and were therefore considered enrolled. 25 patients were assigned a randomization group.
| Milestone | Placebo/ Cimetidine | Cimetidine/ Placebo |
|---|---|---|
| Started | 12 | 13 |
| Completed | 11 | 11 |
| Not completed | 1 | 2 |
| Milestone | Placebo/ Cimetidine | Cimetidine/ Placebo |
|---|---|---|
| Started | 11 | 11 |
| Completed | 11 | 11 |
| Not completed | 0 | 0 |
| Milestone | Placebo/ Cimetidine | Cimetidine/ Placebo |
|---|---|---|
| Started | 11 | 11 |
| Completed | 11 | 11 |
| Not completed | 0 | 0 |
Percent change in erythrocyte total protoporphyrin levels after treatment period versus before.
| Percent change | Placebo | Cimetidine |
|---|---|---|
| Percent Change in Erythrocyte Total Protoporphyrin Level | 5.24 (-6.93 to 17.40) | 10.19 (-4.26 to 24.64) |
Mean daily self-reported outdoor time, in minutes, before EPP/XLP prodrome onset during the last two months of each treatment period, including days without symptoms.
| Minutes per day | Placebo | Cimetidine |
|---|---|---|
| Time to Prodrome | 93.89 (72.33 to 115.45) | 107.21 (85.07 to 129.34) |
PROMIS-57 v2 assesses 7 health domains: Physical Function, Anxiety, Depression, Fatigue, Sleep Disturbance, Ability to Participate in Social Roles and Activities, and Pain Interference. Domain scores are converted to standardized T-scores with a U.S. general population mean of 50 and standard deviation of 10. Higher scores indicate worse outcomes for Anxiety, Depression, Fatigue, Sleep Disturbance, and Pain Interference, and better outcomes for Physical Function and Ability to Participate in Social Roles and Activities. PROMIS-57 v2 was administered immediately before and at the end of each 3-month treatment period. End-of-period PROMIS-57 v2 domain T-scores were analyzed using mixed-effects linear models adjusted for the immediately pre-treatment PROMIS-57 v2 domain T-score for that treatment period, with treatment as a fixed effect and participant as a random effect. Reported values represent least squared means for change in T-score for the cimetidine and placebo treatment periods.
| T-score change | Placebo | Cimetidine |
|---|---|---|
| PROMIS-57 Fatigue Score Change | -1.46 ± 1.9310 | 0.61 ± 1.9310 |
| PROMIS-57 Anxiety Score Change | -2.61 ± 1.65 | -1.33 ± 1.65 |
| PROMIS-57 Ability to Participate in Social Roles and Activities Score Change | 3.41 ± 2.02 | 5.55 ± 2.02 |
| PROMIS-57 Sleep Disturbance Score Change | 0.06 ± 1.31 | 0.8 ± 1.31 |
| PROMIS-57 Physical Function Score Change | 0.70 ± 1.60 | 2.33 ± 1.60 |
| PROMIS-57 Pain Interference Score Change | 0.64 ± 1.63 | -3.56 ± 1.63 |
| PROMIS-57 Depression Score Change | -0.28 (-2.68 to 2.12) | 1.81 (-0.59 to 4.21) |
PROMIS-57 v2 Pain Intensity is a single item scored from 0 to 10, with higher scores indicating worse pain intensity. The instrument-defined possible score range is 0 to 10. This question was administered immediately before and at the end of each 3-month treatment period in this crossover trial. End-of-period PROMIS-57 v2 Pain Intensity scores were analyzed using mixed-effects linear models adjusted for the immediately pre-treatment Pain Intensity score for that treatment period, with treatment as a fixed effect and participant as a random effect. Reported values represent least squared means for change in Pain Intensity scores for the cimetidine and placebo treatment periods.
| Score on a scale change | Placebo | Cimetidine |
|---|---|---|
| Change in PROMIS-57 v2 Pain Intensity Scores From Pre-treatment to End of Each 3-month Treatment Period | -0.27 (-1.19 to 0.64) | -1.27 (-2.19 to -0.36) |
For each participant, the number of phototoxic reactions during the last 2 months of each 3-month treatment period was recorded. In this crossover trial, the reported outcome compares the number of phototoxic reactions per patient during cimetidine with the number during placebo.
| phototoxic episodes per patient | Cimetidine | Placebo |
|---|---|---|
| Number of Phototoxic Reactions Per Participant During the Last 2 Months of Each Treatment Period | 2.0 ± 1.6 | 1.8 ± 2.1 |
Average daily outdoor blue light dose before EPP/XLP prodrome onset during the last two months of each treatment period, including days without symptoms. Dose data for the day were excluded if the patient did not wear the dosimeter for the entire day.
| mJ/cm^2/day | Placebo | Cimetidine |
|---|---|---|
| Blue Light Dose | 6063.10 (4017.57 to 8108.64) | 5985.22 (3502.59 to 8467.85) |
Collected over Throughout the duration of the study; the study duration was approximately 9.5 months per participant. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cimetidine | 0/24 (0%) | 1/24 (4.2%) | 14/24 (58.3%) |
| Placebo | 0/23 (0%) | 1/23 (4.3%) | 7/23 (30.4%) |
| Washout Period | 0/22 (0%) | 0/22 (0%) | 3/22 (13.6%) |
| Event | Cimetidine | Placebo | Washout Period |
|---|---|---|---|
| Urinary tract infectionRenal and urinary disorders | 0/24 | 1/23 | 0/22 |
| DiverticulitisGastrointestinal disorders | 1/24 | 0/23 | 0/22 |
| Event | Cimetidine | Placebo | Washout Period |
|---|---|---|---|
| Upper respiratory infectionRespiratory, thoracic and mediastinal disorders | 8/24 | 2/23 | 1/22 |
| HeadacheNervous system disorders | 2/24 | 3/23 | 1/22 |
| DiarrheaGastrointestinal disorders | 3/24 | 0/23 | 0/22 |
| TransaminitisHepatobiliary disorders | 0/24 | 2/23 | 0/22 |
| NauseaNervous system disorders | 2/24 | 1/23 | 1/22 |
| HeartburnGastrointestinal disorders | 2/24 | 1/23 | 0/22 |
| Age, Continuous(Years) | Placebo/ Cimetidine | Cimetidine/ Placebo | Total |
|---|---|---|---|
| Mean | 44.8 ± 19.4 | 53.2 ± 13.6 | 49.1 ± 16.9 |
| Sex: Female, Male(Participants) | Placebo/ Cimetidine | Cimetidine/ Placebo | Total |
|---|---|---|---|
| Female | 6 | 7 | 13 |
| Male | 6 | 6 | 12 |
| Race (NIH/OMB)(Participants) | Placebo/ Cimetidine | Cimetidine/ Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 12 | 13 | 25 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Placebo/ Cimetidine | Cimetidine/ Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 3 | 3 |
| Not Hispanic or Latino | 12 | 10 | 22 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Placebo/ Cimetidine | Cimetidine/ Placebo | Total |
|---|---|---|---|
| United States | 12 | 13 | 25 |
| Study Site(Participants) | Placebo/ Cimetidine | Cimetidine/ Placebo | Total |
|---|---|---|---|
| MGH | 12 | 12 | 24 |
| UTMB | 0 | 1 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Individual participant data that underlie the results reported in the published article, as well as the study protocol and statistical analysis plan, may be shared, after de-identification (text, tables, figures, and appendices), if meeting the time frame and access criteria listed below.
Supporting information: Study protocol, Statistical analysis plan
Time frame: Beginning 9 months and ending 36 months following article publication
Access criteria: With whom: Researchers who provide a methodologically sound proposal that is approved by the study investigators For what type of analysis: To achieve the aims of the approved proposal. By what mechanisms will the data be available: Proposals should be directed to adickey@mgh.harvard.edu . To gain access, data requestors will need to sign a data access agreement.
Ran from Jun 2022 to primary completion in Apr 2025, 34 months.
Results were first posted in Jun 2026, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cimetidine
Protoporphyria, Erythropoietic →